基本信息:
- 专利标题： Method for treating cancer by co-administration of anticancer agents
- 专利标题（中）：通过联合治疗癌症药物治疗癌症的方法
- 申请号：JP2011121330 申请日：2011-05-31
- 公开(公告)号：JP2011168619A 公开(公告)日：2011-09-01
- 发明人： NAKAHARA TAKAHITO , YAMANAKA KENTARO , KITA AYA , KAMITOKU HIROSHI
- 申请人： Astellas Pharma Inc , アステラス製薬株式会社
- 专利权人： Astellas Pharma Inc,アステラス製薬株式会社
- 当前专利权人： Astellas Pharma Inc,アステラス製薬株式会社
- 优先权： US88280906 2006-12-29; US95077107 2007-07-19
- 主分类号： A61K31/282
- IPC分类号： A61K31/282 ; A61K31/497 ; A61K31/7068 ; A61K33/24 ; A61K39/395 ; A61P35/00 ; A61P43/00
摘要：
PROBLEM TO BE SOLVED: To provide a companion drug having a good antineoplastic effect.
SOLUTION: The present invention relates to therapeutic compositions containing medicament as an active component, particularly 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazine-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium bromide, and is applied in combination with one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, doxorubicin, and dacarbazine, or a retuximab-containing combination therapy of R-DHAP. The therapeutic compositions are useful for the treatment of cancers, preferably all solid cancers and lymphomas, particularly skin cancer, bladder cancer, breast cancer, uterine cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer, and the like. Particularly, they are expected as therapeutic agents for some kinds of cancers which show resistance against other anticancer agents.
COPYRIGHT: (C)2011,JPO&INPIT
摘要（中）：
SOLUTION: The present invention relates to therapeutic compositions containing medicament as an active component, particularly 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazine-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium bromide, and is applied in combination with one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, doxorubicin, and dacarbazine, or a retuximab-containing combination therapy of R-DHAP. The therapeutic compositions are useful for the treatment of cancers, preferably all solid cancers and lymphomas, particularly skin cancer, bladder cancer, breast cancer, uterine cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer, and the like. Particularly, they are expected as therapeutic agents for some kinds of cancers which show resistance against other anticancer agents.
COPYRIGHT: (C)2011,JPO&INPIT
待解决的问题：提供具有良好抗肿瘤效果的伴侣药物。 解决方案：本发明涉及含有作为活性成分的药物，特别是1-（2-甲氧基乙基）-2-甲基-4,9-二氧代-3-（吡嗪-2-基甲基）-4， 9-二氢-1H-萘并[2,3-d]咪唑-3-鎓溴化物，并与一种或多种抗癌剂组合使用，所述抗癌剂选自卡铂，顺铂，紫杉醇，长春瑞滨，吉西他滨，伊立替康， 多柔比星和达卡巴嗪或含有瑞替西单抗R-DHAP的联合疗法。 治疗组合物可用于治疗癌症，优选全部固体癌症和淋巴瘤，特别是皮肤癌，膀胱癌，乳腺癌，子宫癌，卵巢癌，前列腺癌，肺癌，结肠癌，胰腺癌，肾癌，胃癌 癌症等。 特别地，作为对抗其它抗癌剂的抗性的某些癌症，预期它们是治疗剂。 版权所有（C）2011，JPO＆INPIT
信息查询:
EspacenetIPC结构图谱:
| A | 人类生活必需 |
| --A61 | 医学或兽医学；卫生学 |
| ----A61K | 医用、牙科用或梳妆用的配制品 |
| ------A61K31/00 | 含有机有效成分的医药配制品 |
| --------A61K31/045 | .羟基化合物，例如醇类；其盐类，例如醇化物 |
| ----------A61K31/282 | ..铂化合物 |